Arginase shares a common substrate, L-arginine, with nitric oxide (NO) synthase (NOS). It is thought that arginase, if it is expressed in the endothelium, might play a pivotal role in the regulation of NO-mediated vasodilation by reducing the L-arginine availability to NOS. In the present study, we wanted to determine whether arginase is expressed and active in coronary arterioles and to demonstrate whether endothelial arginase can influence NO production and play a functional role in regulating NO-mediated dilation. In this regard, the expression of arginase mRNA and distribution of arginase protein in porcine coronary microvessels were determined by reverse transcription-polymerase chain reaction and immunohistochemistry, respectively. To assess the role of arginase in vasoregulation directly, porcine subepicardial coronary arterioles (60-110 µm in diameter) were isolated, cannulated, and pressurized for in vitro study under the conditions with and without arginase inhibition. Molecular evidence indicated that arginase I, but not arginase II, mRNA was expressed in the coronary arterioles. The constitutive expression of arginase I protein in the coronary arteriolar endothelial cells was revealed immunohistochemically. Adenosine and serotonin stimulated a threefold increase in NO release and produced dilation of isolated coronary arterioles. NOS inhibitor L-NMMA abolished the stimulated NO release and attenuated the dilations in response to these agonists. In contrast to L-NMMA, arginase inhibitor α-difluoromethylornithine (DFMO) increased the NO release by about 80% and also enhanced vasodilations in response to adenosine and serotonin. DFMO inhibited arginase (by 80%), but not NOS, activity in these microvessels without affecting their dilation in response to sodium nitroprusside. Similar to DFMO, intraluminal application of L-arginine enhanced NO-mediated vasodilations. The DFMO-enhanced vasodilation was not observed in the presence of L-NMMA or after endothelial removal, which suggests a regulatory role of endothelial arginase in the NOmediated response. Collectively, this study provides novel findings that the arginase expressed in the endothelium plays a counteracting role in the stimulated NO production, and thus NO-mediated vasodilatory function.
-arginine is the substrate for both nitric oxide (NO) synthase (NOS) and arginase (1, 2) . Thus far, three distinct NOS isoforms have been isolated and purified (3) . Each of these enzymes is involved in the catabolism of l-arginine to form NO and citrulline (4, 5) . NO is a major messenger molecule that has been shown to regulate blood vessel dilation and immune function and to serve as a neurotransmitter in the brain and peripheral nervous system (6) . In endothelial cells, the regulated control of a constitutive NOS allows for the maintenance of vascular tone and normal blood pressure, and it inhibits platelet adherence and aggregation.
A second major pathway of arginine metabolism is via arginase. This classical urea enzyme is involved in the catabolism of L-arginine to ornithine and urea in the liver (7) . Recent studies demonstrated that extrahepatic cells such as endothelia (8) , vascular smooth muscle cells (9) , and macrophages (2, 10) in culture exhibit arginase activity. Although the function of arginase in these extrahepatic cells is not completely understood, we have previously shown in activated macrophages that arginase can compete with NOS for its common substrate L-arginine and thus inhibit NO production (2, 10) . Intravenous administration of arginase can cause constriction of cerebral arterioles and enhance platelet aggregation in mice (11) . These in vivo findings imply that exogenous arginase may influence endothelial function through attenuation of NO production. However, it is unclear whether the arginase, if it is expressed in the endothelium, can play a counteracting role in NO production, and thus for vasoregulation. Furthermore, although two different arginase isoforms (arginase I and II) have been cloned (12, 13) , their vascular localization and relative role in NO-mediated vasoregulation have not been investigated. Therefore, the purpose of the present study was to determine whether arginases are expressed and active in coronary arterioles and to demonstrate whether endothelial arginase can influence NO production and play a functional role in regulating NO-mediated dilation of coronary microvessels.
MATERIALS AND METHODS

General preparation and isolation of coronary microvessels
The techniques for identifying and isolating pig coronary microvessels have been described in detail (14, 15) . Briefly, pigs (8) (9) (10) (11) (12) wk old of either sex) were anesthetized with pentobarbital sodium (20 mg/kg). After a left thoracotomy was performed, the heart was electrically fibrillated, excised, and immediately placed in cold (5Û&SK\VLRORgical salt solution (PSS). The procedures followed were in accordance with guidelines set by the Laboratory Animal Care Committee at Texas A&M University. Each arteriole (50-200 µm in internal diameter in situ) was dissected from the small branches of left anterior descending artery in the subepicardium of left ventricle and then used in the molecular and functional studies described below.
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
Subepicardial pig coronary arterioles (10 vessels/tube, 50-200 µm in diameter with 2-4 mm in length) were dissected under 5Û&366DQGKRPRJHQL]HGLQDPLFURFHQWULIXJHWXEHFRQWDLQLQJ ml TRIZOL Reagent (Life Technologies, Rockville, Md.) and total RNA was isolated according to the manufacturer's instructions. Pig liver and kidney tissues were used as positive controls for the arginase I and II mRNAs, respectively. Sets of primers specific for arginase I (sense : 5'-ACC  CAT CTT TCA CAC CAG CTA CTG-3', antisense: 5'-TGG GTT CAC TTC CAT TAT ATC  TA -3') (12) and arginase II (sense: 5'-GAT CTG CTG ATT GGC AAG AGA CAA-3',   L   antisense: 5'-CTA AAT TCT CAC ACG TGC TTG ATT-3') (13) genes and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, gene accession no. U48832, sense: 5'-CCA CCC ACG  GCA AGT TCC ACG GCA-3', antisense: 5'-GGT GGT GCA GGA GGC ATT GCT GAC-3') gene were engineered (Sigma-Genosys, The Woodlands, Tx.) for use in RT-PCR reactions. Equal amounts of total RNA for each sample were annealed to the 3'-specific primers and RT reaction was performed by using Thermoscript RT (Life Technologies) according to the manufacturer's procedure. To determine whether the PCR reaction was amplifying genomic DNA, a first-strand cDNA synthesis reaction was performed with and without RT. RT cDNA (2 OVDPSOHZHUHXVHd to perform a PCR reaction in a 50-µl volume containing 10× buffer, 1.5 mM MgCl 2 , 0.4 mM dNTP, 0.1 µg/µl of each primer, and 3.5 U of the Expand High Fidelity PCR enzyme (Roche, Indianapolis, Ind.). The PCR reaction was initiated with a denaturation step at 94Û& PLQ IROORZHG E\ F\FOHV RI Û& IRU V GHQDWXUDWLRQ Û& IRU V (annealing), and 72Û& IRU V H[WHQVLRQ XVLQJ D *HQH$PS 7KHUPRF\FOHU $SSOLHG Biosystems, Foster City, Calif.). The PCR reaction was terminated with a final step at 72Û& min). These PCR conditions provided RT-PCR products for arginase genes that were within the linear assay range. The PCR amplified products were electrophoresed on a 1.8% agarose gel and visualized with ethidium bromide staining.
Immunohistochemical analysis
Isolated coronary arterioles (~100-150 µm in diameter in situ) were embedded in OCT compound 4583 (Tissue-Tek). The embedded vessel was frozen and sectioned at -15°C in a Leica CM1850 Cryostat (Meyer Instruments, Houston, Tx.). The sectioned slides were dried at room temperature for 20 min, fixed in 4% paraformaldehyde-PBS for 1 h, and then rinsed 3 times (5 min each) in PBS. The tissue slides were incubated with blocking diluent (5% milk powder, 5% normal goat serum, and 1% BSA in PBS) at room temperature for 1 h and then with mouse anti-arginase I monoclonal antibody (1:40 dilution, Transduction Laboratories, Lexington, Ky.) at 4°C overnight. The slides were rinsed 3 times (5 min each) in PBS and then incubated with the secondary antibody, goat anti-mouse monoclonal antibody conjugated with biotin (1:60 dilution, Jackson ImmunoResearch Laboratories, West Grove, Pa.), at room temperature for 1 h. Afterwards, the slides were rinsed 3 times (5 min each) in PBS and then were incubated with fluorescein avidin D (1:35 dilution, Vector Laboratories, Burlingame, Calif.) at room temperature for 60 min. Subsequently, the slides were covered by a coverslip and then dried at room temperature overnight. Staining control tissues were exposed for the same duration to nonimmune mouse serum (1:40 dilution, Jackson ImmunoResearch Laboratories) in place of primary antibody. We observed the slides and analyzed them by using the Ultima-Z 312 Confocal Microscope (Meridian Instruments, Okemos, Mich.).
Functional assessment of isolated coronary arterioles
Isolated coronary arterioles (60-110 µm in internal diameter in situ) were cannulated with PSSfilled micropipettes in a Lucite vessel chamber. After cannulation of an arteriole, the chamber was transferred to the stage of an inverted microscope (model IM35, Zeiss, Thornwood, N.Y.). The vessel was pressurized without flow at 60 cm H 2 O by a reservoir system. Internal diameter of the vessel was measured throughout the experiment by using video microscopic techniques as described previously (15) . The cannulated arterioles were bathed in PSS at 36-37Û& WR DOORZ development of basal tone. After vessels developed a stable basal tone, the dilation of arterioles to endothelium-dependent agents adenosine (1 nM to 10 µM) and serotonin (0.1 nM to 10 µM) and to endothelium-independent agent sodium nitroprusside (1 nM to 10 µM) was established. The contributions of NOS and arginase in these vasodilations were examined by treating the vessels with the respective inhibitors N G -monomethyl-L-arginine (L-NMMA, 10 µM, 30 min extraluminal incubation) and DFMO (0.4 mM, 30 min intraluminal incubation; a gift from Ilex Oncology, San Antonio, Tex.). The role of the endothelium in the vasodilations to adenosine and serotonin after DFMO treatment was determined by endothelial removal with CHAPS (0.4%). The techniques for endothelial denudation were described in our previous studies (16, 17) . To ensure that the vascular smooth muscle function was not compromised by CHAPS treatment, concentration-dependent dilation of the vessel in response to sodium nitroprusside (1 nM to 10 µM) was examined before and after denudation.
Only vessels that exhibited normal basal tone, showed no vasodilation to endothelium-dependent vasodilator bradykinin (1 nM), and showed unaltered vasodilation to sodium nitroprusside after endothelial removal was accepted for data analysis. Of the 11 vessels 2 were excluded from data analysis because of impaired dilation to sodium nitroprusside after denudation. Because the inhibition of arginase by DFMO could presumably increase NO production by NOS through increased intracellular levels of L-arginine, we also examined whether administration of Larginine could enhance NO-mediated vasodilations. In this regard, coronary arteriolar dilations to adenosine (1 µM), serotonin (0.1 µM), and sodium nitroprusside (1 µM) were examined before and after intraluminal incubation with L-arginine (3 mM). The specificity of L-arginine was examined by treating the vessels with D-arginine (3 mM). Drugs were obtained from Sigma (St. Louis, Mo.), except as specifically stated. All drugs used for the functional study were dissolved in PSS.
NO assay
NO production from coronary arterioles was evaluated by measuring nitrite with a chemiluminescence NO analyzer (Siever Instruments, Boulder, Colo.) as described previously (17) . Vessels (10 vessels/tube, ~100 µm in diameter with 1-2 mm in length) were isolated and placed in a microcentrifuge tube containing 100 µl PSS. After a 30 min initial incubation, at 37Û& O RI DGHQRVLQH ILQDO FRQFHQWUDWLRQ 0 RU VHURWRQLQ ILQDO FRQFHQWUDWLRQ 0 was added to the vessel bath. The bathing solution was then collected for NO measurement after a 25 min incubation with these agents. Another series of experiments was performed in the presence of either DFMO or L-NMMA. The vessels were pretreated with DFMO (0.4 mM) or L-NMMA (10 µM) for 30 min and then adenosine (1 µM final concentration) or serotonin (0.1 µM final concentration) was added to the vessel bath and NO production was assayed after a 25 min incubation. In addition, two separate experiments ran parallel to the above protocol as control groups by adding either vehicle solution (PSS) or by pretreating with DFMO (0.4 mM) without subsequent addition of agonists. The protein levels in each tube were quantified by bicinchoninic acid protein assay (Pierce, Rockford, Ill.) and were used as a basis to normalize the NO production.
Arginase assay
Coronary arterioles (7 vessels/tube, ~100 µm diameter with 1-2 mm in length) were isolated and placed in a microcentrifuge tube containing 100 µl PSS. The vessels were sonicated and then freeze-dried in PSS. After the tissue was resuspended in 150 µl of lysis buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 0.1 mM phenylmethylsulfonyl fluoride), the arginase activity in the absence or presence of DFMO (0.4 mM) was determined from the urea production by using the method described by Corraliza et al (18) . In brief, vessel lysate (50 µl) was added into 75 µl of Tris· HCl (50 mM; pH 7.5) containing 10 mM MnCl 2 . We activated arginase by heating the mixture at 55-60Û&IRUPLQ We carried out the hydrolysis reaction of L-arginine by arginase by incubating the mixture containing activated arginase with 50 µl of L-arginine (0.5 M; pH 9.7) at 37°C for 1 h and stopped the process by adding 400 µl of the acid solution mixture (H 2 SO 4 :H 3 PO 4 :H 2 O=1:3:7). For colorimetric determination of urea, α-isonitrosopropiophenone (25 µl, 9% in absolute ethanol) was then added and the mixture was heated at 100°C for 45 min. After we placed the sample in the dark for 10 min at room temperature, the urea concentration was determined spectrophotometrically by the absorbance at 550 nm measured with a microplate reader (Molecular Devices, Sunnyvale, Calif.). The amount of urea production, after normalization with protein, was used as an index for arginase activity.
NOS assay
Coronary arterioles (6 vessels/tube, ~100 µm diameter with 1-2 mm in length) were isolated and placed in a microcentrifuge tube containing 100 µl lysis buffer: 50 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 5.0 mM EGTA, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1 % NP-40 with Complete protease inhibitors (Roche, Indianapolis, Ind.). The vessel samples were sonicated and then solubilized on ice for 30 min. The vessel lysate (60 µl) was mixed with 60 µl of reaction mixture (final concentrations: 0.63 mM NADPH, 25 µM tetrahydrobiopterin, 0.25 µM FAD, 5 mM L-arginine, 5 µg/ml calmodulin, 5 mM EGTA, and 0 or 1.25 mM CaCl 2 ) and incubated at 37°C for 1 h. After centrifugation (2,000 g for 2 min), 100 µl of the sample supernatant was collected for nitrite measurement as described in the NO Assay above. A control reaction at nominally zero calcium (0 mM CaCl 2 in the presence of 5 mM EGTA) from the reaction mixture served as a blank. NOS activity was calculated as: NOS activity in 1.25 mM Ca 2+ -NOS activity in 0 mM Ca 2+ . The amount of nitrite production, after normalization with protein, was used as an index for NOS activity
Data analysis
At the end of each experiment, the vessel was relaxed with sodium nitroprusside 100 µM to obtain its maximal diameter at 60 cm H 2 O intraluminal pressure (19) . All diameter changes in response to agonists were normalized to the vasodilation in response to 100 µM sodium nitroprusside and expressed as a percentage of maximal dilation. All data are presented as mean ± SE. Statistical comparisons of vasomotor responses and NO production under various treatments were performed with two-way ANOVA when appropriate and tested with Fisher's protected least significant difference multiple range test. Arginase and NOS activities were compared by a paired Student's t-test. Significance was accepted at P < 0.05.
RESULTS
Arginase mRNA expression in coronary arterioles
We determined whether arginase mRNA is present in the isolated coronary arterioles by using RT-PCR. Figure 1 shows that the arginase I transcript (131 bp) was detected in the liver (positive control) and coronary arterioles after PCR. In contrast, from the same sample of total RNA, arginase II mRNA (360 bp) was not detected. The arginase II transcript, however, was revealed in the kidney (positive control). Equivalent levels of GAPDH (311 bp) transcripts were detected in the liver, kidney, and arterioles.
Localization of arginase I in coronary arterioles
To determine the cellular localization of arginase I in the coronary arteriole, isolated subepicardial arterioles were subjected to immunohistochemical study. The background level of staining was determined in the vessels treated with the nonimmune mouse serum, secondary antibody, and fluorescein avidin D (Fig. 2A) . In the presence of anti-arginase I monoclonal antibody, high levels of immunostaining, as represented by a pseudocolor spectral display, were detected in both the endothelial and smooth muscle cells (Fig. 2B) .
Effect of NOS and arginase inhibitors on coronary arteriolar dilations
The putative role of endothelial arginase in modulating vasodilation was examined in isolated coronary arterioles with basal tone; that is, 64±1% of maximal diameter (132±3 µm) at 60 cm H 2 O intraluminal pressure and 37Û&EDWKWHPSHUDWXUH$GHQRVLQHFig. 3A) and serotonin (Fig.  3B ) produced a concentration-dependent dilation of coronary arterioles. In the presence of NOS inhibitor L-NMMA (10 µM), the basal vascular tone was slightly increased but did not reach statistical significance (before L-NMMA: 64±1% of maximal diameter; after L-NMMA: 62±2% of maximal diameter); however, the dilation of these vessels to adenosine and to serotonin was significantly inhibited (Fig. 3) . In another set of experiments, the vessels were pretreated with arginase inhibitor, DFMO (0.4 mM), and the dilations to adenosine and serotonin were reexamined. The resting vascular tone was not altered by DFMO (before DFMO: 63±1%; after DFMO: 65±2%); however, in contrast to L-NMMA, DFMO potentiated vasodilations in response to adenosine (Fig. 3A) and serotonin (Fig. 3B) . The potentiated effect of DFMO was eliminated by subsequent administration of L-NMMA to these vessels (Fig. 3) .
To demonstrate the specific effect of L =-NMMA and DFMO on endothelial function, the dilation of coronary arterioles to endothelium-independent vasodilator sodium nitroprusside was examined. It was found that these two inhibitors, either administered independently or simultaneously, did not affect vasodilation to sodium nitroprusside (Fig. 4A) , which suggests that the altered vasodilations to adenosine and serotonin were not caused by the nonspecific effect of these inhibitors on vascular smooth muscle function. The effect of DFMO on arginase and NOS activities is shown in Figure 4B . In the absence of DFMO, arginase activity was 206±14 nmol urea/g protein and NOS activity was 156±27 nmol nitrite/g protein (Fig. 4B) . DFMO significantly reduced arginase activity to 41±6 nmol urea/g protein without affecting NOS activity (149±35 nmol nitrite/g protein) demonstrating the efficacy and specificity of DFMO in inhibiting arginase activity.
Role of endothelial NO in DFMO-potentiated vasodilation
To address whether the potentiated effect of DFMO on adenosine-and serotonin-induced dilation requires an intact endothelium, the coronary arteriolar dilation to these two agonists was examined in the denuded vessels after DFMO treatment. Endothelial denudation was verified by the complete block of bradykinin-induced dilation (Control: 85±6% dilation vs. Denudation: 4±2% dilation). Vascular smooth muscle function remained intact in these vessels because vasodilation to sodium nitroprusside was not altered after denudation (data not shown). Endothelial denudation caused a significant inhibition of coronary arteriolar dilations to adenosine (Fig. 5A) and serotonin (Fig. 5B) . This inhibition was identical to that produced by L-NMMA as shown in Figure 3 . In these denuded vessels, DFMO did not potentiate vasodilations in response to adenosine (Fig. 5A) and serotonin (Fig. 5B) .
DFMO Enhances NO Production
Because L-arginine is a common substrate for NOS and arginase, we speculate that inhibition of the arginase pathway in the endothelium, and thus increased arginine availability, would enhance the amount of NO released in response to adenosine or serotonin. To support this contention, coronary arteriolar production of NO in response to adenosine and serotonin in the presence and absence of NOS and arginase inhibitors was examined. In the absence of agonists, only a small amount of NO was produced from coronary arterioles (about 60±11 nmol nitrite/g protein, Fig.  6 ). However, NO production was significantly increased by adding adenosine (Fig. 6A) or serotonin (Fig. 6B) to the vessels. These agonist-stimulated NO productions were inhibited by L-NMMA. Conversely, NO production in response to adenosine and to serotonin was significantly enhanced by arginase inhibitor DFMO (Fig. 6) . DFMO did not alter NO production in the absence of agonists.
L-Arginine enhances NO-mediated coronary arteriolar dilation
Because DFMO enhances NO production, we suggest that inhibition of arginase increases intracellular levels of L-arginine, and thus its availability, for NO synthesis. To examine whether the increase of L-arginine supply can enhance the NO-mediated vasodilatory responses, coronary arteriolar dilations to adenosine (1 µM), serotonin (0.1 µM), and sodium nitroprusside (1 µM) were examined before and after intraluminal incubation with L-arginine (3 mM). We found that L-arginine treatment did not affect resting vascular tone but significantly increased the vasodilations to adenosine and serotonin (Fig. 7) . In contrast, L-arginine had no effect on the vasodilation in response to sodium nitroprusside (Fig. 7) . D-Arginine (3 mM) treatment had no effect on the vasodilations to adenosine and serotonin (n=3, data not shown).
DISCUSSION
The results of the present study indicate that arginase can play a functional role in regulating NO-mediated dilation in the coronary microcirculation. Specifically, we demonstrated that coronary arteriolar endothelial cells express arginase. Inhibition of its activity enhances the stimulated NO production, and thus increases arteriolar dilation. It appears that arginase is an endogenous competitor of NOS for their common substrate L-arginine and consequently influences NO-mediated vasomotor function through the regulation of substrate availability. This finding is imperative in the microcirculation because these vessels are the primary regulators of blood flow in the tissue. To provide a perspective for our observations and conclusions, the results from the present study will be discussed below in reference to previous findings regarding the putative control of NO-mediated vasodilatory function by NOS and arginase.
It is well established that vascular endothelial cells produce NO from L-arginine via a constitutive NOS. The endothelium-derived NO is an important endogenous vasodilator that regulates vascular tone (20, 21) . We have shown in previous studies that coronary arteriolar dilations to adenosine (17) and serotonin (19) are partially inhibited after endothelial removal. The extent of inhibition is identical to that produced by NOS inhibitors L-NAME (17, 19, 22) and L-NMMA (Fig. 3) , which suggests that these vasodilatory responses are mediated in part by activation of endothelial NOS. This idea was directly supported by the increased nitrite production, the primary decomposition product of NO in hemoglobin-free solution (23) , in coronary arterioles stimulated with adenosine or serotonin. In accord with the functional data, the increased NO production was inhibited by the NOS inhibitor L-NMMA, which further indicates that NO is the mediator responsible for the endothelium-dependent component of adenosine-and serotonin-induced coronary arteriolar dilation.
Besides the NOS isoforms, arginase is another major L-arginine-consuming enzyme that converts L-arginine to L-ornithine and urea. Arginase is expressed most abundantly in the liver for ammonia detoxification via the urea cycle. Although recent studies have indicated that some extrahepatic tissues/cells, which do not possess a complete urea cycle enzymes, also express arginase, the biological role of this extrahepatic arginase remains unclear. In activated macrophages, we have recently demonstrated that arginase can compete with inducible NOS for L-arginine and thus inhibits NO production (2) . Previous studies have shown that cultured aortic (24) and coronary (8) endothelial cells can produce urea and ornithine, which suggests the expression of arginase in this cell type. Administration of exogenous arginase can influence vasomotor tone of cerebral arterioles in vivo (11) .
We speculate that arginase, if it is expressed in the endothelium, might play a pivotal role in the regulation of NO-mediated vasodilation by reducing the L-arginine availability to NOS. However, there is no report on the endogenous role of arginase in this respect, and it is unclear whether vascular arginase can regulate NO-mediated vasodilation. In the present study, we documented that arginase inhibitor DFMO (25) significantly enhanced endothelium-dependent NO-mediated coronary arteriolar dilations to adenosine and serotonin, but did not alter the dilation to an endothelium-independent vasodilator, sodium nitroprusside.
These results suggest that inhibition of arginase specifically affects the NO-mediated vasodilatory pathway at the upstream of smooth muscle cells because the relaxation of vascular smooth muscle to an NO donor (i.e., sodium nitroprusside) was not compromised by DFMO. It appears that the arginase that resides in the endothelium contributes to the regulation of NOmediated vasodilation. This contention is supported by the evidence that the stimulated NO production from coronary arterioles was significantly increased by DFMO and that the effect of DFMO was observed only in the vessels with an intact endothelium. The enhanced NO-mediated vasodilation by DFMO is not a result of increased NOS activity because this inhibitor did not alter either resting NO production or NOS enzyme activity. It is speculated that the enhanced NO production might be a result of increased L-arginine availability to NOS. If this speculation is true, we would expect to observe an enhanced NO-mediated vasodilation by increasing the supply of L-arginine. Indeed, exogenous administration of L-arginine, but not D-arginine, to arterioles specifically enhanced NO-mediated vasodilations to adenosine and serotonin. This Larginine-dependent NO response was also observed in various microvascular beds (11, 26, 27) , including human coronary microvessels (28) . These results indicate that L-arginine can be a limiting factor for the stimulated NO synthesis in the microvessels. In this regard, the arginase expressed in the endothelium might compete with NOS for their common substrate L-arginine and thus influence NO production.
Two distinct arginase isoforms have been identified: arginase I in the liver and arginase II in extrahepatic tissues (7) . Although arginase I is generally considered as the hepatic isoform, recent studies have shown that extrahepatic macrophages (10, 29) , neutrophils (29) , lung tissue (30) , and nephritic glomeruli (31) also express arginase I mRNA and protein. However, the expression and cellular localization of arginase isoforms have not yet been revealed in intact blood vessels. Our present findings, using RT-PCR, showed that arginase I, but not arginase II, mRNA was expressed in the coronary arterioles. The cellular localization of arginase I, as detected by immunohistochemistry, appears to be in both the endothelium and vascular smooth muscle. These findings demonstrate a constitutive expression of arginase I in the intact blood vessel and physically support a functional role of endothelial arginase in modulating NOmediated dilation of coronary arterioles.
In conclusion, the present study provides the first evidence, at both the molecular and functional levels, for a biological role of arginase in the coronary microcirculation. Our results suggest that coronary arteriolar dilations to adenosine and serotonin are mediated in part by the endothelial release of NO, which is regulated by the activity of NOS and arginase. It appears that the arginase expressed in endothelial cells can contribute to the regulation of NO-mediated vascular function. In this regard, the L-arginine catabolism via arginase pathway, in addition to the regulation of NOS enzyme and its cofactors, can act as an endogenous negative control system to regulate overall NO production and thus the NO-mediated biological function. Many studies have demonstrated that vascular dysfunction associated with hypercholesterolemia (19, (32) (33) (34) , diabetes (35) , and hypertension (36) can be related to the deficiency of L-arginine availability for NO production in endothelial cells. However, the endogenous regulation of the L-arginine pool for NOS remains elusive. Our results not only demonstrate a role of arginase in modulating NOmediated vascular function but also provide a speculation of its contribution to the vascular dysfunction during disease states. This contention is supported by recent evidence that arginase activity can be increased by diabetes (37) and hypertension (38) and also induced by inflammatory stimuli (29) and certain cytokines (9, 10) in various cell types. It is conceivable that the NO-mediated biological function can be compromised if an up-regulation of arginase occurs under these pathophysiological conditions. n=10; (B) . NOS inhibitor L-NMMA (10 µM) attenuated vasodilations to adenosine (n=5) and serotonin (n=5). Arginase inhibitor DFMO (0.4 mM) enhanced vasodilatory responses to adenosine (n=5) and serotonin (n=5). Subsequent administration of L-NMMA to the DFMO-pretreated vessels attenuated the vasodilations to adenosine and serotonin, and there was no significant difference compared with these dilations in the presence of L-NMMA alone. Diameter changes to agonists were normalized to the maximal vasodilation in response to 100 µM sodium nitroprusside and expressed as a percentage of maximal dilation. *P < 0.05 DFMO vs. control; † P < 0.05 Control and DFMO vs. L-NMMA and L-NMMA+DFMO. 4 . A) Isolated coronary arterioles dilated in a concentration-dependent manner to endothelium-independent agent sodium nitroprusside (n=10). Neither NOS inhibitor L-NMMA (10 µM, n=5) nor arginase inhibitor DFMO (0.4 mM, n=5) altered this vasodilatory response. Administration of L-NMMA to the DFMO-pretreated vessels also did not affect vasodilation to sodium nitroprusside. Diameter changes to sodium nitroprusside were normalized to the maximal vasodilation in response to 100 µM sodium nitroprusside and expressed as a percentage of maximal dilation. B) DFMO (0.4 mM) significantly inhibited arginase activity (i.e., urea production) in vessel lysate, but did not affect NOS activity (i.e., nitrite production). NOS activity was calculated as: NOS activity in 1. 25 Arginase inhibitor DFMO (0.4 mM) did not affect vasodilations to adenosine and serotonin in these denuded vessels. Diameter changes to agonists were normalized to the maximal vasodilation in response to 100 µM sodium nitroprusside and expressed as a percentage of maximal dilation. *P < 0.05 vs. Control. tone (before L-arginine: 64±2%; after L-arginine: 66±2%), but increased vasodilations to adenosine (1 µM; n=4) and serotonin (0.1 µM; n=4). L-Arginine had no effect on vasodilation to sodium nitroprusside (1 µM; n=4). Diameter changes to agonists were normalized to the maximal vasodilation in response to 100 µM sodium nitroprusside and expressed as a percentage of maximal dilation.
